Name

TANAKA, Masako

TACHIBANA, Masako

Official Title

Assistant Professor(without tenure)

Affiliation

(Waseda Institute for Advanced Study)

Contact Information

Mail Address

Mail Address
tanakamsk@aoni.waseda.jp

Address・Phone Number・Fax Number

Address
2-2 Wakamatsu-cho, Shinjuku-ku, Tokyo 162-8480, Japan
Phone Number
+81-3-5369-7491

URL

Grant-in-aids for Scientific Researcher Number
00733651

Sub-affiliation

Sub-affiliation

Faculty of Science and Engineering(School of Advanced Science and Engineering)

Educational background・Degree

Educational background

-2003/03 Osaka City University Faculty of Science Department of Biology
-2005/03 Osaka City University Graduate School of Science Department of Biology and Geosciences
-2014/03 Osaka City University Graduate School of Medicine

Career

-2008/06National Institute for Agro-Environmental Science
-2010/03Osaka City UniversityFaculty of Medicine
-2014/03Japan Society for the Promotion of ScienceResearch Fellowship for Young Scientists
-2017/03Osaka City UniversityGraduate School of Medicine

Academic Society Joined

The Japanese Pharmacological Society

Japanese Cancer Association

Research Field

Keywords

Chemoresistance,Interactome,Chaperone

Grants-in-Aid for Scientific Research classification

Medicine, dentistry, and pharmacy / Boundary medicine / Applied pharmacology

Biological Sciences / Oncology / Tumor diagnostics

Paper

Hsp70 inhibitors suppress androgen receptor expression in LNCaP95 prostate cancer cells

Kita K, Shiota M, Tanaka M et al.

Cancer Sci. Peer Review Yes 2017/07-

PubMedDOIlink

Macrophage-derived exosomes induce inflammatory factors in endothelial cells under hypertensive conditions

Osada-Oka M, Shiota M, Izumi Y, Nishiyama M, Tanaka M et al.

Hypertens Res. Peer Review Yes 40(4) p.353 - 3602017-

PubMedDOIlink

Protection of stromal cell-derived factor 2 by heat shock protein 72 prevents oxaliplatin-induced cell death in oxaliplatin-resistant human gastric cancer cells

Takahashi K, Tanaka M, Yashiro M, Matsumoto M, Ohtsuka A, Nakayama KI, Izumi Y, Nagayama K, Miura K, Iwao H, Shiota M.

Cancer Letters Peer Review Yes 378(1) p.8 - 152016-

PubMedDOIlink

Identification of low-abundance proteins in serum via the isolation of HSP72 complexes

Tanaka M, Shiota M, Nakao T, Uemura R, Nishi S, Ohkawa Y, Matsumoto M, Yamaguchi M, Osada-Oka M, Inagaki A, Takahashi K, Nakayama KI, Gi M, Izumi Y, Miura K, Iwao H.

Journal of Proteomics Peer Review Yes 136p.214 - 2212016-

PubMedDOIlink

Myeloid HIF-1 attenuates the progression of renal fibrosis in murine obstructive nephropathy

Tateishi Y, Osada-Oka M, Tanaka M, Shiota M, Izumi Y, Ishimura E, Motoyama K, Inaba M, Miura K.

Journal of Pharmacological Sciences Peer Review Yes 127(1) p.181 - 1892015-

DOIlink

Repeated remote ischemic conditioning attenuates left ventricular remodeling via exosome-mediated intercellular communication on chronic heart failure after myocardial infarction

Yamaguchi T, Izumi Y, Nakamura Y, Yamazaki T, Shiota M, Sano S, Tanaka M, Osada-Oka M, Shimada K, Miura K, Yoshiyama M, Iwao H.

Int J Cardiol. Peer Review Yes 178p.239 - 2462015-

PubMedDOIlink

Establishment of neutralizing rat monoclonal antibodies for fibroblast growth factor-2

Tanaka M, Yamaguchi M, Shiota M, Kawamoto Y, Takahashi K, Inagaki A, Osada-Oka M, Harada A, Wanibuchi H, Izumi Y, Miura K, Iwao H, Ohkawa Y.

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy Peer Review Yes 33(4) p.261 - 2692014-

PubMedDOIlink

Hsc70 contributes to cancer cell survival by preventing Rab1A degradation under stress conditions

Tanaka M, Mun S, Harada A, Ohkawa Y, Inagaki A, Sano S, Takahashi K, Izumi Y, Osada-Oka M, Wanibuchi H, Yamagata M, Yukimura T, Miura K, Shiota M, Iwao H.

PLoS One Peer Review Yes 9(5) p.e967852014-

PubMedDOIlink

Lipid synthesis is promoted by hypoxic adipocyte-derived exosomes in 3T3-L1 cells

Sano S, Izumi Y, Yamaguchi T, Yamazaki T, Tanaka M, Shiota M, Osada-Oka M, Nakamura Y, Wei M, Wanibuchi H, Iwao H, Yoshiyama M.

Biochemical and Biophysical Research Communications Peer Review Yes 445(2) p.327 - 3332014-

PubMedDOIlink

Establishment of a 5-fluorouracil-resistant triple-negative breast cancer cell line

Takahashi K, Tanaka M, Inagaki A, Wanibuchi H, Izumi Y, Miura K, Nagayama K, Shiota M, Iwao H.

International Journal of Oncology Peer Review Yes 43(6) p.1985 - 19912013-

PubMedDOIlink

Pravastatin-induced proangiogenic effects depend upon extracellular FGF-2

Shiota M, Hikita Y, Kawamoto Y, Kusakabe H, Tanaka M, Izumi Y, Nakao T, Miura K, Funae Y, Iwao H.

Journal of Cellular and Molecular Medicine 16(9) p.2001 - 20092011-

PubMedDOIlink

Generation of a rat monoclonal antibody specific for hsp72

Tanaka M, Shiota M, Okada S, Harada A, Odawara J, Mun S, Iwao H, Ohkawa Y.

Hybridoma Peer Review Yes 30(4) p.397 - 4002011-

PubMedDOIlink

Generation of a rat monoclonal antibody specific for heat shock cognate protein 70

Shiota M, Saiwai H, Mun S, Harada A, Okada S, Odawara J, Tanaka M, Iwao H, Ohkawa Y.

Hybridoma Peer Review Yes 29(5) p.453 - 4562010-

PubMedDOIlink

Sensitive stages for photoperiodic induction of pupal diapause in the flesh fly Sarcophaga similis (Meade) (Diptera: Sarcophagidae)

Tanaka M, Tachibana S-I, Numata H.

Applied Entomology and Zoology Peer Review Yes 43(3) p.403 - 4072008-

link

Books And Publication

Folia Pharmacological Japonica

塩田正之、田中昌子(Joint authorship)

The Japanese Pharmacological Society2014-

Detali

Responsible Number of Pages:310-312

Research Grants & Projects

Grant-in-aids for Scientific Research Adoption Situation

Research Classification:

HSP72 interactome identifies key molecules for intrinsic resitance to gemcitabine in pancreatic cancer

2014/-0-2016/-0

Allocation Class:¥2730000

On-campus Research System

Special Research Project

SDF-2の機能解析に基づいたオキサリプラチン耐性機序の解明

2017Collaborator:合田 亘人

Research Results Outline:オキサリプラチンは腫瘍の縮小効果が高い抗がん剤である。しかし、早期に耐性が生じるため、耐性の解除が化学療法における重要な課題である。申請者はこれまでにオキサリプラチンは腫瘍の縮小効果が高い抗がん剤である。しかし、早期に耐性が生じるため、耐性の解除が化学療法における重要な課題である。申請者はこれまでにキサリプラチンの新規耐性因子としてStromal cell-derived factor 2 (S...オキサリプラチンは腫瘍の縮小効果が高い抗がん剤である。しかし、早期に耐性が生じるため、耐性の解除が化学療法における重要な課題である。申請者はこれまでにキサリプラチンの新規耐性因子としてStromal cell-derived factor 2 (SDF-2) を同定した。しかし、SDF-2が耐性を生じさせる分子機構については明らかにできていない。そこで本研究はSDF-2の分子機能の解析を中心に、オキサリプラチンの耐性機構の解明を目的とした。その結果、SDF-2はオキサリプラチンだけではなくツニカマイシンやタプシガルギンといった小胞体ストレス (UPR) の誘導剤によってもタンパクレベルが上昇することから小胞体におけるストレス応答に関与している可能性が示唆された。しかし、このタンパクレベルの上昇は遺伝子発現を伴わないこと、またSDF-2のノックダウンがUPRシグナルに影響を与えないことから、SDF-2がUPRを直接的に制御して耐性を生じさせている可能性は低いと考えらえる。

Lecture Course

Course TitleSchoolYearTerm
Advanced Life Science and Medical Bioscience LaboratorySchool of Advanced Science and Engineering2019spring semester
Life Science and Medical Bio-science Laboratory IISchool of Advanced Science and Engineering2019spring semester
Life Science and Medical Bio-science Laboratory II [S Grade]School of Advanced Science and Engineering2019spring semester
Molecular Oncology ASchool of Advanced Science and Engineering2019spring semester
Advanced Molecular Oncology AGraduate School of Advanced Science and Engineering2019spring semester

Visiting - Interlocking-time or Part-time Lecturers of Other Institutions, etc.

2017/04- 2018/03Osaka City University